21.41% More Acasti Pharma Inc – Class A (NASDAQ:ACST) Shorted Shares

Acasti Pharma Inc. (NASDAQ:ACST) Corporate Logo

It was reported an increase on Acasti Pharma Inc – Class A (NASDAQ:ACST)’s shorted shares with 21.41%. It was issued in December by FINRA the 520,500 shorted shares on ACST. Previously was reported up change of 21.41% from 428,700 shares. With Average volume 172,400, ACST’s previous position will take 3 days to restore.

Ticker’s shares touched $0.6658 during the last trading session after 1.71% change.Currently Acasti Pharma Inc. is downtrending after 57.02% change in last December 8, 2017. ACST has also 361,251 shares volume. ACST underperformed the S&P500 by 72.64%.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.The firm is worth $52.56 million. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia.Last it reported negative earnings.

For more Acasti Pharma Inc. (NASDAQ:ACST) news announced recently go to: Seekingalpha.com, Nasdaq.com, Globenewswire.com, Marketwired.com or Nasdaq.com. The titles are as follows: “Acasti Pharma’s (ACST) CEO Jan D’Alvise on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” announced on November 14, 2018, “Mid-Afternoon Market Update: Stitch Fix Falls After Q4 Results; Pyxus International Shares Climb – Nasdaq” on October 02, 2018, “Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option – GlobeNewswire” with a publish date: October 23, 2018, “Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada – Marketwired” and the last “Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares – Nasdaq” with publication date: October 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.